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A b s t r a c t
Background: Bisoprolol is one of the most widely used beta-blockers characterised by cardioselectivity, and it has no intrinsic 
sympathomimetic activity. It is commonly used in the treatment of coronary heart disease and heart failure.
Aim: The aim of study was to assess the bioequivalence of the film-coated tablets containing 2.5 mg of bisoprolol (Bisocard® 
— the medicinal product) to the original medicinal product (Concor Cor 2.5® — the reference). 
Methods: A randomised, open-label, two-period, crossover, single-dose, relative bioavailability study was conducted in fasted 
healthy Caucasian volunteers. A single 10-mg oral dose (four tablets of 2.5 mg) of the test or reference product was followed 
by a 14-day wash-out period, after which the subjects received the alternative product. Blood was sampled within a period 
of 60 h post administration in pre-specified time points. Bisoprolol concentrations were determined by a validated LC-MS/MS 
method. The products were considered bioequivalent if the 90% confidence interval (CI) of the log-transformed geometric 
mean ratios (test vs. reference) for AUC(0-t), AUC(0-∞), and Cmax were within 80–125% limits. Adverse events were monitored 
during the study based on the subject claims and clinical parameters. 
Results: Twenty-six healthy male and female volunteers (mean age ca. 29 years; body mass index 22.7 kg/m2) were in-
cluded in the study, and 24 completed the clinical part. The geometric mean ratios (test/reference) for the log-transformed 
AUC(0-t), AUC(0-∞), and Cmax were 95.16% (90% CI 92.52–97.87%), 95.08% (90% CI 92.40–97.83%), and 100.00% (90% CI 
94.83–105.45%), respectively. There were no significant differences in the pharmacokinetic parameters between the test and 
reference formulations. No serious adverse events were reported. 
Conclusions: The results of this single-dose study in healthy Caucasian volunteers indicate that Bisocard®; 2.5 mg film-coated 
tablets are bioequivalent to the reference product — Concor Cor 2.5®; 2.5 mg film-coated tablets. Both products had similar 
safety profile and have been well tolerated.
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INTRODUCTION
Bisoprolol is a highly selective b1-receptor antagonist devoid of 
any partial agonist effect (intrinsic sympathomimetic activity), 
vasodilatory effect, or membrane stabilising properties. It is 
well absorbed from the gastrointestinal tract and undergoes 
minimal first-pass metabolism to achieve oral bioavailability 
of ca. 90%. Due to its relatively long elimination half-life 
(10–11 h) it is suitable for a once daily administration [1]. 
It is cleared in equal parts unchanged by the kidney and by 
biotransformation in the liver [2].
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Bisoprolol is marketed worldwide and its indications in-
clude hypertension, coronary heart disease, and stable chronic 
heart failure [2]. It is a b-blocker shown to improve survival 
in an outcome trial [3]. In hypertension or angina pectoris 
the usual therapeutic dose is 5–10 mg, and the maximum 
recommended dose is 20 mg. In heart failure the initial dose 
of bisoprolol fumarate is 1.25 mg, and it is gradually increased 
to 10 mg [2]. Beta-blockers are the most commonly used 
medicines in the therapy of hypertension; they may be used 
as monotherapy or concomitantly with other drugs. Despite 
the continuous rise in their prescription rate, bisoprolol and 
other b-blockers remain underused and underdosed in the 
treatment of heart failure and other cardiac diseases [4, 5]. 
It may be partially due to the limited number of available 
generic formulations. 
The aim of this study was to evaluate the relative 
bioavailability of two oral bisoprolol formulations following 
a single dosing in healthy subjects in order to investigate the 
bioequivalence of the test bisoprolol film-coated tablet (Biso-
card® by ICN Polfa Rzeszow S.A.) to the reference bisoprolol 
film-coated tablet (Concor Cor 2.5® by Merck KGaA).
METHODS
Study drugs
The following bisoprolol fumarate film-coated tablets were 
administered during the study: the test product Bisocard® 
manufactured by ICN Polfa Rzeszow S.A., Rzeszow, Poland 
(lot No. 80018173; expiration date: January 2011) and the 
reference product Concor Cor 2.5® manufactured by Merck 
KGaA, Beerse, Belgium (lot No. 5787020; expiration date: 
July 2011).
Study participants
The number of participants was determined assuming a sig-
nificance level a = 0.05, power of test 1 — b = 0.80, and 
ratio of the geometric mean of primary pharmacokinetic 
parameters (test vs. reference product) between 0.95 and 
1.05. It was estimated that the intra-subject variability of pri-
mary pharmacokinetic parameters would not exceed 21% [6], 
while the drop-out rate would not exceed 15%. Based on 
the above assumptions, 26 subjects were included and 
22 should complete the study. 
There were 54 healthy volunteers invited for the screen-
ing — women and men aged between 18 and 55 years, whose 
body mass index was 18.8–24.9 kg/m2. After a social interview 
and medical history, each of the volunteers underwent a medi-
cal examination and additional tests: electrocardiography 
(ECG), chest X-ray examination, urine testing (general and 
toxicological, pregnancy test in women) and blood — hae-
matology, blood chemistry as well for the serology (human 
immunodeficiency virus HIV, hepatitis B and C).
The exclusion criteria included: evidence or suspected 
pathology assessed on the basis of the conducted tests; sus-
pected hypersensitivity to bisoprolol or other ingredients of the 
medicinal product; second- or third-degree atrioventricular 
block; systolic blood pressure below 100 mm Hg; bradycardia 
below 50 bpm; chronic or acute inflammation or infection; 
allergy symptoms requiring medical treatment; any condition 
that could affect the pharmacokinetics of the investigational 
product, as well as any clinically significant abnormality in 
laboratory test results. It was decided to exclude volunteers 
who had taken any medications in the period of two weeks 
prior to the study or a drug with a half-life of over 24 h in the 
period of four weeks prior to the enrolment. Also excluded 
were those who had taken part in any other study in the last 
60 days prior to the screening, cigarette smokers, alcohol 
abusers, and those with a special diet (vegetarians) or a specific 
lifestyle (professional sports). Before admission to the clinical 
centre qualified volunteers were tested for the presence of 
prohibited substances in urine, alcohol, and exhaled air.
Study design
The study was designed — in compliance with the applicable 
guidelines of the European Medicines Agency (EMA) [7, 8] 
— as a randomised, cross-over, two-way trial following the 
administration of a single dose of the test and reference prod-
uct in fasting conditions. Study documents were approved by 
the Committee on Bioethics at the Regional Medical Chamber 
(Warsaw, Poland) and the Central Register of Clinical Trials at 
the Office for Registration of Medicinal Products, Medical 
Devices, and Biocidal Products (Warsaw, Poland). The trial 
was assigned the EudraCT number 2009-014861-20.
The clinical part of the study was conducted at the Clini-
cal Centre CRO Poland (Otwock, Poland) in accordance with 
the contents of the Declaration of Helsinki and Good Clinical 
Practice guidelines [9]. Before the screening all volunteers 
were informed about the study procedures, risks, insurance, 
and limitations resulting from their participation in the study. 
The volunteers were supplied with a clinical trial information 
form and were allowed to ask questions to obtain additional 
information. Each volunteer who declared to take part in the 
study signed an informed consent form.
Drug administration
The volunteers qualified to participate in the study arrived at 
the test centre the day before the administration (D-0). The 
next day (D-1) in the morning, after at least a 10-h period of 
fasting, each volunteer received — under medical supervision, 
in a sitting position — a single dose of 10 mg (four tablets of 
2.5 mg) of the test or reference product with 250 mL water 
according to the randomisation table. When swallowed, the 
doctor checked the inside of the mouth to confirm the swal-
lowed dose. The volunteers remained in the clinical centre for 
the next 4 h resting, sitting, or half-sitting, and could perform 
normal activities, provided that they stayed within the prem-
ises of the clinical centre. Two hours after the ingestion of the 
test or reference product the subjects were allowed to drink 
water in order to secure their fluid balance. All participants 
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stayed at the clinical site for at least 12 h before and 60 h after 
the administration of the test or reference product, in each of 
the two study periods. During their stay all study participants 
ate only standardised meals provided by the clinical centre.
Blood sampling
To determine the concentration of bisoprolol in the plasma, in 
each of the two study periods 18 blood samples were taken 
from each volunteer: sample “0” (15 mL) within 60 min before 
the drug administration, then (9 mL) after 0.33, 0.67, 1, 1.5, 
2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, 48, and 60 h. The total 
volume of blood collected from each participant during the 
whole study was less than 370 mL. Samples were collected by 
syringe with an intravenous cannula of “Venflon” placed in the 
forearm venous vessel, and then the blood was poured into 
labelled test tubes placed in an ice bath. The blood samples 
were centrifuged for 10 min at 4°C at 4000 rpm. The plasma 
separated from each sample was transferred to two labelled 
polypropylene tubes (primary and backup), and then placed 
in a freezer at –20°C.
Bioanalysis 
The bisoprolol plasma concentrations were determined by high 
performance liquid chromatography coupled with tandem mass 
spectrometry (LC-MS/MS). The bioanalysis was performed in 
compliance with the principles of Good Laboratory Practice in 
the Pharmacology Department of the Pharmaceutical Research 
Institute, Warsaw. The applied bioanalytical method included 
slight modifications to the previous reports [6, 10, 11]. Refer-
ence standards of bisoprolol fumarate and metoprolol tartrate 
(the internal standard [IS]), were purchased from USP and 
Sigma-Aldrich (St. Louis, MO, USA), respectively.
The LC-MS/MS analyses were performed using a Quat-
tro Micro API triple quadrupole mass spectrometer (Waters, 
Manchester, UK) and an Alliance 2695 series liquid chroma-
tograph with a gradient pump, an autosampler with a cooler, 
a column oven, and a vacuum degasser (Waters, Milford, 
MA, USA). The data was processed using MassLynx version 
4.1 software (Waters, Manchester, UK). The chromatographic 
separation from endogenous compounds was performed on 
a Zorbax SB-C18 column (150 × 3.0 mm, 3.5 µm, Agilent 
Technologies, CA, USA) preceded by a C18 guard column 
(4 × 2 mm, Phenomenex, Torrance, CA, USA). Isocratic elu-
tion was applied with the mixture of methanol and 0.01 M 
ammonium acetate containing 0.1% formic acid (62:38 v/v). 
The flow rate of the mobile phase was set at 0.3 mL/min and 
the run time was 6 min. The column and the autosampler 
were maintained at 35 ± 1°C and 20 ± 3°C, respectively. The 
MS/MS was equipped with an electrospray ionisation source, 
and multiple reaction monitoring in the positive ion detection 
mode was used. The transitions of 326.34 Æ 116.14 m/z and 
268.29 Æ 191.12 m/z were applied for the bisoprolol and 
IS, respectively. The desolvation temperature was 350°C with 
the nitrogen flow of 700 L/h. The capillary voltage was 3.5 kV 
and the source temperature was 80°C. The cone voltage of 
32 V for bisoprolol and 30 V for the IS was selected. The cell 
collision energy was 19 eV for both bisoprolol and the IS. 
Argon was used as the collision gas.
A frozen human plasma sample was thawed at an ambi-
ent temperature, mixed, and centrifuged. A 1.0 mL aliquot of 
the plasma was mixed with 50 µL of the IS working solution 
(20 µg/mL). Then the sample was alkalised by the addition of 
0.1 M sodium hydroxide. Afterwards, 5 mL of ethyl acetate 
was added and the mixture was shaken for 5 min on a vortex 
mixer. After centrifugation, the aqueous phase was frozen, 
and the organic layer was transferred to a glass tube and 
evaporated to dryness under a stream of nitrogen. The dry 
residue was reconstituted in 200 µL of 60% aqueous methanol 
and mixed. The solution was transferred into an autosampler 
vial, and 30 µL of this solution was injected into the column.
Pharmacokinetic parameters
AUC(0-t) (i.e. area under the plasma concentration – time curve from 
time zero to time t of the last quantifiable concentration), AUC(0-∞) 
(i.e. area under the concentration – time curve from time zero 
extrapolated to infinity) and Cmax (i.e. maximum bisoprolol con-
centration in plasma) were selected as primary parameters. The 
secondary parameters were: tmax (time to reach maximum biso-
prolol concentration in plasma), t1/2 (elimination half-life), and 
MRT (mean residence time of bisoprolol in the body).
Cmax and tmax were recorded from plasma concentrations 
directly. The elimination rate constant (kel) — estimated using 
three or four last measured concentrations — allowed us to 
calculate t1/2 according to the formula ln 2/kel. AUC(0-t) was 
obtained by the linear trapezoidal method with linear inter-
polation until the last measured concentration (Ct). The sum of 
AUC(0-t) and Ct/kel, was used to calculate AUC(0-∞). AUMC (i.e. 
area under the time course of the statistical first moment curve) 
was divided by AUC(0-∞) to obtain MRT. A non-compartmental 
pharmacokinetic analysis was performed using the WinNonlin 
version 5.0.1., (Pharsight Corp.).
Statistical analysis
Shapiro-Wilk, Kolmogorow-Smirnow, Cramer-von Mises and 
Anderson-Darling tests at the significance level a = 0.05 were 
used to assess the normality of data distribution. Following 
the ln-transformation of AUC(0-t), AUC(0-∞), Cmax, t1/2, and 
MRT, the analysis of variance (ANOVA) was performed using 
the General Linear Models procedure. It was assumed that 
bioequivalence is confirmed in cases when 90% confidence 
interval (CI) calculated for tested vs. reference product geo-
metric means ratio — for each primary pharmacokinetic pa-
rameter (i.e. AUC(0-t), AUC(0-∞), and Cmax) — is included within 
acceptance criteria of 80–125% (p < 0.05) [7, 8, 12, 13]. For 
tmax non-transformed data was analysed using two one-sided 
nonparametric Mann-Whitney-Wilcoxon tests. Statistical 
calculations were performed using SAS for Windows, version 
9.1.3. (SAS Institute, N.C., USA).
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Safety analysis
The study participants were monitored in order to assess 
potential side effects. Upon admission to the clinical centre, 
every 12 h during their stay and at the end of the study their 
vital signs (pulse rate, blood pressure, body temperature) were 
measured. Blood samples were drawn to check the mor-
phology and basic biochemical parameters. The investigator 
evaluated the recorded adverse events (AE) and decided on 
the need to implement therapeutic actions.
RESULTS
Out of 47 male and female volunteers invited 36 signed up 
to participate in the study. The volunteers — after signing an 
informed consent — were screened (medical history, physical 
examination, ECG, chest X-ray, blood and urine laboratory 
tests). The blood and urine samples were analysed in a certi-
fied clinical laboratory of Mazovian Centre for Lung Diseases 
and Tuberculosis in Otwock, Poland. After the screening five 
persons were found to be ineligible and another five persons 
were eligible but not randomised. Finally, 26 healthy volun-
teers (demographic data in Table 1) were enrolled, and 24 of 
them completed the clinical part of the study. One of the 
volunteers left the study during wash-out, not willing to par-
ticipate, while another one was withdrawn due to AE during 
the second period of the study.
Validation of the bioanalytical method 
The validation parameters were defined according to the EMA 
as well as the Food and Drug Administration guidelines [7, 8, 
14]. The validation covered all required tests: the carry-over 
effect, matrix effect, selectivity (analysis of blank human 
plasma samples derived from six volunteers), extraction re-
covery, limit of detection and lower limit of quantification, 
linearity, accuracy and precision, stability and system suitability 
tests. The stability of bisoprolol was tested in solutions and 
in biological material under appropriate test conditions and 
storage time (short-term, long-term, freeze and thaw, and 
autosampler stability). All parameters met the pre-defined 
acceptance criteria.
The calibration curve, constructed by plotting the peak 
area ratios of bisoprolol to the IS against the nominal con-
centrations of bisoprolol, was linear within the range 0.3– 
–70.0 ng/mL. The accuracy and precision of the method were 
determined using three concentrations of bisoprolol in plasma 
(0.9, 30.0, and 60.0 ng/mL). The 90% CI for the intra-run 
(within one day) and inter-run (within three days) accuracy 
were within the ranges 93.1–111.1% and 89.8–109.5%, re-
spectively. The intra-run and inter-run precision was within 
the ranges 1.89–7.03% and 3.04–9.20%, respectively.
Pharmacokinetic evaluation of bioequivalence 
No relevant differences between the tested and reference drug 
in the bisoprolol plasma concentration vs. time profiles (Fig. 1) 
nor calculated pharmacokinetic parameters (Table 2) were 
observed. The statistical analysis did not allow us to discard the 
null hypothesis regarding the ln-normal distribution of AUC(0-t), 
AUC(0-∞), Cmax, t½, and MRT. As expected, the distribution of tmax 
differed significantly from the ln-normal one, which confirmed 
that the choice of a nonparametric test to evaluate this param-
eter was appropriate. The ANOVA results (Table 3) enabled 
the construction of 90% CI. The acceptance criteria were 
met for all primary pharmacokinetic parameters (Table 2). 
The Mann-Whitney-Wilcoxon test revealed no statistically 
significant differences between tmax of the tested and reference 
product, and the descriptive statistics for this parameter were 
comparable for both products.
Safety results 
All 26 study participants who received at least one dose of 
the test/reference product were included in the safety assess-
ment. There were no serious adverse events, six AEs reported 
in three volunteers were described as moderately severe and 






Age [years]* 18–43 [29]
Height [cm]* 158–191 [172] 
Weight [kg]* 47.5–84.0 [67.9]
BMI [kg/m2]* 18.8–24.9 [22.7]
*min–max [arithmetic mean]; BMI — body mass index
Figure 1. Mean ± standard deviation bisoprolol plasma con-
centration – time profiles after administration of single 10-mg 
oral doses (four film-coated tablets of 2.5 mg) of the tested 
(Bisocard®) and reference (Concor COR 2.5®) products
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included headache, increased body temperature, nausea, and 
vomiting. The occurrence of headache and vomiting found 
in one of the volunteers was classified as probably related to 
the study medicinal product, other AEs were not associated 
with the study products. All adverse events resolved during the 
study. There were no significant changes in blood and urine 
parameters (blood cell count, liver, and kidney) obtained after 
the completion of the clinical part of the study. 
DISCUSSION 
Bisoprolol is a highly selective b1-receptor antagonist. It dis-
plays no intrinsic sympathomimetic activity nor membrane 
stabilising properties. Bisoprolol is well absorbed following 
oral administration, and its bioavailability reaches 90%. Its 
pharmacokinetics are linear and age-independent. It seems 
that fasting or fed conditions do not influence bisoprolol 
pharmacokinetics. Ca. 30% of the drug is binded by proteins, 
and its volume of distribution is 3.5 L/kg [3].
The administration of bisoprolol in chronic heart failure 
and/or coronary artery disease patients is associated with 
a reduction in heart rate, increase in heart rate variability, 
and the improvement of left ventricular function [3]. Clinical 
efficacy of bisoprolol was primarily demonstrated in patients 
with chronic heart failure — in two large, double-blind, 
multi-centre randomised clinical trials: CIBIS and CIBIS II [15, 
16]. The included patients with chronic heart failure (NYHA 
class III or IV) were randomly assigned to receive bisoprolol 
(starting dose of 1.25 mg daily, increased to a maximum of 
5 mg [CIBIS] or 10 mg daily [CIBIS II]) or placebo. The pa-
tients also received a standard therapy in heart failure (ACE 
inhibitor and diuretic). It was observed that the addition of 
a highly selective b1-blocker bisoprolol significantly improved 
patient survival and reduced the hospitalisation rate. The use 
of bisoprolol is generally well tolerated in patients. According 
to the current guidelines b-blockers like bisoprolol constitute 
basic treatment for patients with chronic heart failure and 
stable angina, and are also used — among others — in the 
treatment of hypertension or arrhythmias [17–20]. 
Bisoprolol generics are used in a large number of patients 
and in many clinical conditions. It follows that the bioequiva-
lence of these drugs to the reference product should be care-
fully studied, as was the case here. In our study we evaluated 
the bioequivalence of Bisocard® 2.5 mg film-coated tablets, 
manufactured by ICN Polfa Rzeszow S.A., with the reference 
product. The study was performed in line with the valid EMA 
guidelines [7, 8]. Since the end of study, some regulatory 
changes have been introduced, but general bioequivalence 
rules remain unchanged, so our study is in line with the cur-
rent EMA requirements [21]. 
Appropriate selection of volunteers for bioequivalence 
studies guarantees a minimised variability within the study 
group and allows the detection of possible differences be-
tween the drugs [7]. In order for the measurement of bisoprolol 
plasma levels to be reliable, high enough concentrations were 
obtained because the study was conducted after a single dose 
of 10 mg — administered as four 2.5 mg film-coated tablets. 
Table 3. Results of the ANOVA (performed with the fixed effects model) of ln-transformed pharmacokinetic parameters after  
a single 4 × 2.5-mg dose administration of test and reference products to healthy volunteers (n = 24). The statistically significant 
effects are presented in bold
Pharmacokinetic parameter Source of variation/p value
Sequence Subject within sequence Formulation Period
AUC(0-t) 0.006 < 0.001 0.006 0.014
AUC(0-∞) 0,012 < 0.001 0.006 0.012
Cmax 0.001 < 0.001 0.999 0.461
Abbreviations — see text
Table 2. Pharmacokinetic parameters of bisoprolol after a single 4 × 2.5-mg dose administration of the test and the reference 





Geometric mean test/reference 
(90% CI)
AUC(0-t) (ng×h/mL) 541 ± 79 570 ± 98 95.16 (92.52–97.87)
AUC(0-∞) (ng×h/mL) 548 ± 80 578 ± 99 95.08 (92.40–97.83)
Cmax (ng/mL) 44.2 ± 9.6 43.9 ± 8.3 100.00 (94.83–105.45)
tmax [h]* 1.5 [1.0–3.0] 1.5 [0.7–3.0] –
t1/2 [h] 8.6 ± 1.7 8.9 ± 1.4 –
MRT [h] 12.4 ± 1.9 12.8 ± 1.9 –
*Median and [min–max] for tmax; CI — confidence interval; SD — standard deviation; rest abbreviations — see text
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Based on the half-life of bisoprolol reported 10 to 11 h [1], 
a 14-day wash-out between the study periods was found to 
be appropriate. The correct selection of this parameter was 
confirmed as bisoprolol concentration in all the pre-dose 
samples below the limit of quantification (0.3 ng/mL). 
For each primary parameter, the a posteriori power of the 
study was higher than 0.90, which confirmed the correct num-
ber of volunteers. The study results are an interesting example 
in which the factors determined during ANOVA as statistically 
significant are not clinically relevant because the acceptance 
criteria for all primary parameters were met (i.e. 90% CI for 
the ratio of geometric means were contained entirely within 
80–125% limits). In our study very low intra-subject variabil-
ity was recorded, and as a consequence other factors — i.e. 
sequence, formulation, and period — became statistically 
significant contributors to the variability observed in the study.
The sampling schedule allowed proper characterisation of 
tmax and Cmax because there were no pharmacokinetic profiles 
(a specific study period for a specific subject) where Cmax was 
the first point after the drug administration. In each pharma-
cokinetic profile AUC(0-t) was greater than 80% of AUC(0-∞), 
which confirmed the appropriate selection of the last blood 
sampling point as well as a suitable bioanalytical method 
sensitivity. A positive study result is similar to the analogous 
bioequivalence study of Bisocard® 10 mg film-coated tablets 
[22]. It is also consistent with the recent meta-analysis that 
confirmed the efficacy and safety of generic drugs used in the 
treatment of cardiovascular diseases [23].
CONCLUSIONS
The results of the study conducted in healthy Caucasian 
volunteers after a single 10-mg administration in fasting 
conditions indicate that Bisocard® 2.5 mg film-coated tablets 
manufactured by ICN Polfa Rzeszow S.A. (tested product) 
are bioequivalent to Concor Cor 2.5®; 2.5 mg film-coated 
tablets manufactured by Merck KGaA (reference product). 
Both products were safe and did not cause any clinically 
relevant adverse events.
Conflict of interest: The study was sponsored by ICN Polfa 
Rzeszow S.A.
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S t r e s z c z e n i e
Wstęp: Bisoprolol jest jednym z najczęściej stosowanych beta-adrenolityków cechujących się kardioselektywnością i pozba-
wionym wewnętrznej aktywności sympatykomimetycznej. Jest powszechnie stosowany w leczeniu choroby niedokrwiennej 
serca czy niewydolności serca. 
Cel: Celem pracy była ocena równoważności biologicznej tabletek powlekanych zawierających bisoprolol w dawce 2,5 mg 
(Bisocard® — lek badany) w odniesieniu do oryginalnego produktu leczniczego (Concor Cor 2.5® — lek referencyjny). 
Metody: Przeprowadzono badanie otwarte z randomizacją w schemacie krzyżowym, po pojedynczym podaniu na czczo 
zdrowym ochotnikom rasy białej bisolprololu w dawce 10 mg (4 tabletki po 2,5 mg). Próbki krwi pobierano do 60. godziny 
po podaniu leku. Stężenie bisoprololu w osoczu oznaczono zwalidowaną metodą LC-MS/MS. Produkty lecznicze uznano 
za równoważne biologicznie, gdy 90-procentowe przedziały ufności (CI) stosunków średnich geometrycznych (produkt ba-
dany/referencyjny) dla zlogarytmowanych AUC(0-t), AUC(0-∞) i Cmax mieściły się w granicach 80–125%. Działania niepożądane 
monitorowano na podstawie parametrów klinicznych i zgłoszeń ochotników. 
Wyniki: Dwudziestu sześciu zdrowych ochotników obu płci (średnia wieku ok. 29 lat, wskaźnik masy ciała 22,7 kg/m2) zostało 
włączonych do badania, a 24 z nich ukończyło część kliniczną badania. Otrzymano następujące stosunki średnich geome-
trycznych (produkt badany/referencyjny): AUC(0-t) 95,16% (90% CI 92,52–97,87%), AUC(0-∞) 95,08% (90% CI 92,40–97,83%) 
oraz Cmax 100,00% (90% CI 94,83–105,45%). Nie zaobserwowano istotnych statystycznie różnic w ocenianych parametrach 
farmakokinetycznych między produktami badanym i referencyjnym. Nie stwierdzono poważnych zdarzeń niepożądanych 
w badanej populacji. 
Wnioski: W badanej populacji stwierdzono równoważność biologiczną leku generycznego (Bisocard®) z produktem referen-
cyjnym (Concor Cor 2.5®). Oba produkty cechują się porównywalną, dobrą tolerancją i bezpieczeństwem.
Słowa kluczowe: bisoprolol, farmakokinetyka, równoważność biologiczna, względna dostępność biologiczna, beta-adrenolityk 
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